Patient Gateway

RSS Feed

Durvalumab in the Real-World Management of Extensive-Stage Small Cell Lung Cancer in Alberta: Clinical Outcomes, Treatment Patterns, and a Proof-of-Concept for Outcomes-Based Agreements

Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer

Radiosurgery Linked to Longer Lung Cancer Survival - Legal Reader

Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn

FDA Application Withdrawn for I-DXd in Small Cell Lung Cancer

Daiichi Sankyo, Merck withdraw bid for accelerated approval of I-DXd in small cell lung cancer

Concomitant medications and outcomes of bispecific T-cell engager therapy: A propensity-matched study of tarlatamab in ES-SCLC